Phosphodiesterase 5 (PDE5) inhibitors (eg, sildenafil, tadalafil) do not appear to reduce the risk of Alzheimer disease and related dementias, according to a National Institutes of Health (NIH) study.

May 25, 2006 — Three new studies presented here at the 2006 annual meeting of the American Urological Association support the use of phosphodiesterase-5 (PDE-5) inhibitors for the resolution of lower ...

A research-driven evaluation assessing the comparative effectiveness of phosphodiesterase type 5 (PDE5) inhibitors is contributing to ongoing clinical discourse around vascular-mediated functional ...

There is a class of drugs called “Phosphodiesterase-5 inhibitors” (PDE5 inhibitors.) Such drugs in this class are known as sildenafil, vardenafil, tadalafil, and avanafil.1 These drugs all work by ...

Please provide your email address to receive an email when new articles are posted on . Treatment with sildenafil or tadalafil was not associated with a reduced risk for incident Alzheimer’s disease ...

Urologic surgeon Jose M. Flores, MD is lead author of a new study investigating the risk of biochemical recurrence after radical prostatectomy when taking ED drugs. There have been conflicting studies ...

Men with primary organic erectile dysfunction (ED) are less likely than those with primary psychogenic ED to adhere to treatment with PDE5 inhibitors. Men with primary organic erectile dysfunction (ED ...

(HealthDay News) — Use of phosphodiesterase type 5 (PDE5) inhibitors does not appear to increase the risk of melanoma, according to the conclusions of a meta-analysis published online in the Journal ...

CORVALLIS, Ore., May 8, 2025 /PRNewswire/ -- Karma Biosciences announced today that it has applied for patent protection for two new drug formulations utilizing its proprietary excipient Zenergy™ .

SaveHealth reports that choosing an erectile dysfunction medication involves comparing effectiveness, side effects, and costs, emphasizing generics for affordability.